GEN-MKT-18-7897-A
Jan 24, 2017 | Biopharma, Blogs | 0 comments
Have you ever wished for a compact instrument that delivers expert-level answers to your most complex biotherapeutic characterization challenges faster and easier than what you are doing now? At SCIEX, we recognize that even expert users want easier ways to perform daily characterization tasks and get great results every time. That’s why we set out to develop the X500B QTOF system: a robust and reliable new instrument and software solution that reduces complexity and simplifies biologics characterization workflows so every scientist can get expert-level results.Download Info Pack >
Flexible and Robust: The X500B QTOF Makes Standard Characterization Workflows a Breeze
The new X500B QTOF system is the first true benchtop, high-resolution mass spectrometer designed specifically for characterization of complex biologics, delivering high-quality data for intact mass and peptide mapping analyses–including post-translational modification identification–and characterization of antibody-drug conjugates. The system utilizes the renowned SCIEX Turbo V™ ionization source and a heated TOF path for maximum robustness and reproducibility. Add to that the new SCIEX OS Operating System and BioPharmaView™ data processing software, which are surprisingly easy to learn and operate.
The new X500B system enables you to:
As a part of the SCIEX 360º Innovation for Biologics Characterization strategy, the X500B QTOF system is designed to help you get better answers, faster. For standard biologics characterization workflows, the compact X500B system is the next “big” thing to improve your lab’s productivity and throughput.
Download your free information pack showing how simple it is to set up your biologics characterization, including:
Finding the right information shouldn’t slow you down. Whether you’re troubleshooting your mass spec, learning something new, or optimizing performance, access to the right resources at the right moment makes all the difference.
As an analytical strategy, middle-down mass spectrometry (MS) workflows characterize biotherapeutic proteins by analyzing large, digested protein fragments or defined subunits, rather than fully intact proteins (top-down) or digested peptides (bottom-up). A middle-down strategy combines the strengths of top-down and bottom-up approaches by delivering high sequence coverage and structural specificity while maintaining relatively simple sample preparation. In practice, middle-down analysis enables accurate mass measurement, rapid sequence confirmation, and localization of key post-translational modifications (PTMs) on protein subunits that are directly relevant to product quality.
In biopharmaceutical development, sequence variants (SV) are considered an inherent risk of producing complex proteins in living systems. Sequence variants are unintended changes to the amino acid sequence of a biotherapeutic and can be caused by errors in transcription or translation in the host cell, or cell culture and process conditions. Detailed analysis of SVs is important in process and product development to ensure the drug’s safety and efficacy. Even low‑level sequence variants can have significant implications for product quality, safety, and efficacy, making their accurate detection and characterization a critical requirement across development, process optimization, and regulatory submission.
Posted by
You must be logged in to post a comment.
Share this post with your network